Cognition Therapeutics, Inc. reported topline results from its Phase 2 COG2201 ‘MAGNIFY’ trial, demonstrating that oral zervimesine (CT1812) treatment slowed the rate of geographic atrophy (GA) lesion growth by 28.6% compared to placebo. The observed GA lesion area was reduced by 28.2% at 18 months compared to placebo.
These results validate zervimesine’s potential across degenerative disease indications, showing its impact on retinal cell health and function. The study indicated that zervimesine binds to the sigma-2 receptor, which regulates the ability of retinal cells to take in low-density lipoprotein, a process damaged in dry AMD.
Despite these positive clinical data, the company had previously announced a strategic decision in January 2025 to voluntarily conclude this study to focus resources on its Alzheimer’s disease and dementia with Lewy bodies programs. This decision was not due to any safety concerns related to zervimesine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.